Durect
- Country
- Ownership
- -
- Employees
- 58
- Market Cap
- -
- Introduction
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
Clinical Trials
15
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
- Conditions
- Alcoholic Hepatitis
- Interventions
- Drug: DUR-928 30 mgDrug: Placebo+ Standard of Care (SOC)Drug: DUR-928 90 mg
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Durect
- Target Recruit Count
- 307
- Registration Number
- NCT04563026
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Southern California Research Center, Coronado, California, United States
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Durect
- Target Recruit Count
- 2
- Registration Number
- NCT04447404
- Locations
- 🇺🇸
Site 03, Newark, New Jersey, United States
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: DUR-928 Topical SolutionDrug: Vehicle Topical Solution
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Durect
- Target Recruit Count
- 25
- Registration Number
- NCT03837743
- Locations
- 🇺🇸
Site 01, San Diego, California, United States
🇺🇸Site 04, Miami, Florida, United States
🇺🇸Site 05, Tampa, Florida, United States
A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
- Conditions
- Alcoholic Hepatitis
- Interventions
- Drug: DUR-928 90 mgDrug: DUR-928 150 mgDrug: DUR-928 30 mg
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Durect
- Target Recruit Count
- 19
- Registration Number
- NCT03432260
- Locations
- 🇺🇸
DURECT Study Site 0001, San Diego, California, United States
🇺🇸DURECT Study Site 007, Miami, Florida, United States
🇺🇸DURECT Study Site 0004, Atlanta, Georgia, United States
A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Durect
- Target Recruit Count
- 5
- Registration Number
- NCT03394781
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Southern Therapy and Advanced Research, Jackson, Mississippi, United States
- Prev
- 1
- 2
- 3
- Next